Matt Miksic
Stock Analyst at Barclays
(0.81)
# 1966
Out of 5,218 analysts
242
Total ratings
59.69%
Success rate
8.65%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Zimmer Biomet Holdin... | Maintains: Underweight | 125 118 | 106.86 | 10.42% | 6 | Dec 12, 2024 | |
Edwards Lifesciences | Maintains: Overweight | 85 88 | 73.33 | 20.01% | 22 | Dec 2, 2024 | |
Medtronic | Maintains: Overweight | 105 109 | 82.47 | 32.17% | 15 | Nov 26, 2024 | |
Alphatec Holdings | Maintains: Overweight | 19 20 | 9.63 | 107.68% | 1 | Nov 19, 2024 | |
Insulet | Maintains: Equal-Weight | 220 234 | 269.59 | -13.2% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 60 | 32.68 | 83.6% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 143 149 | 113.45 | 31.34% | 24 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 402 418 | 375.05 | 11.45% | 20 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 27 | 18.26 | 47.86% | 10 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 78 86 | 90.16 | -4.61% | 12 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 85 93 | 82.33 | 12.96% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 138 113 | 77.21 | 46.35% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 490 510 | 539.38 | -5.45% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 16 | 13.75 | 16.36% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 61 | 51.57 | 18.29% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 17 18 | 18.59 | -3.17% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 52 54 | 30.37 | 77.81% | 15 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 158 162 | 146.69 | 10.44% | 10 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 84.14 | 14.1% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 76.59 | 30.57% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 235.25 | 77.68% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 13.15 | 112.93% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 19.75 | 239.24% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 14.2 | 3280.28% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 24.06 | 261.6% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 3.38 | 639.64% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 9.17 | -1.85% | 1 | Dec 12, 2016 |